Stock YPH ASTELLAS PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Insiders Astellas Pharma Inc. Deutsche Boerse AG

Equities

YPH

JP3942400007

Market Closed - Deutsche Boerse AG
Other stock markets
 03:49:53 2024-07-11 pm EDT 		5-day change 1st Jan Change
9.128 EUR +0.33% Intraday chart for Astellas Pharma Inc. +2.68% -16.87%
Jul. 02 Astellas Pharma Inc. Announces the Center for Drug Evaluation of the China National Medical Products Administration Approves Xtandi (Enzalutamide) for the Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer CI
Jun. 03 US FDA Acknowledges Astellas Pharma's Resubmission of Biologics License Application for Zolbetuximab MT

Insiders

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Astellas Pharma Inc. Announces Board and Committee Retirements
CI
INTERVIEW - Naoki Okamura, CEO of Astellas Pharma: business strategy and healthcare outlook
MT
Astellas Pharma Rejigs Top Management
MT
Astellas Pharma Inc. Announces Executive Changes
CI
Astellas Pharma Inc. Announces CEO Changes, Effective April 1, 2023
CI
Astellas Pharma Inc. Appoints Steve Sabus as Chief Commercial Officer
CI
Syndax Pharmaceuticals Names Steve Sabus Chief Commercial Officer
MT
Astellas Pharma Inc. Announces Executive Changes
CI
Astellas Pharma Inc. Announces Keiko Yamagami to Resign as Director
CI
Astellas Announces Executive Changes
CI
Astellas Establishes Global Patient Centricity Leadership Structure
CI
Astellas Pharma Inc. Announces Directorate and Committee Resignations
CI
Astellas Appoints David Fryrear as New Global Head of Clinical and Research Quality Assurance Organization
CI
Astellas Pharma Inc. Announces Executive Promotions
CI
Astellas Pharma Inc. Announces Executive Promotions and New Hire in Legal, IP and Immuno-Oncology
CI
Astellas Announces Executive Changes
CI
Astellas Announces Promotion of Lei Ding to Vice President, Payer Strategy, Contracts and Pricing
CI
Astellas Promotes Rodrigo Fernandez to Vice President, Latin America
CI
Astellas Promotes David Abbott to National Vice President Key Account Management
CI
Astellas Pharma : Named to FTSE4Good Index Series for the Seventh Consecutive Year
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4503 Stock
  4. YPH Stock
  5. News Astellas Pharma Inc.
  6. Insiders